FINHUB Insights

REGN · Q2 FY25 · Apr 1 – Jun 30, 2025

Regeneron Pharmaceuticals Q2 FY25: where the revenue came from and where it went

Regeneron Pharmaceuticals Q2 FY25: revenue $3.7B (+4% year over year). Net profit $1.4B. Largest cohort Collaboration Revenue $1.9B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2025
Reported
Aug 1, 2025 10-Q
Sankey diagram of Regeneron Pharmaceuticals's income statement for Q2 FY25: revenue of $3.7 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$3.7B +4% year over year
Gross profit$3.4B 93% margin
Operating profit$1.1B 29% margin
Net profit$1.4B 38% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
ItemValueShare of revenueYear over year
Revenue 3.7 100% +4%
Collaboration Revenue 1.9 51% +22%
Product 1.6 43% −15%
Product and Service Other 0.2 5% +76%
Cost of revenue−0.38%
Gross profit3.493% margin+0pp
Research & development−1.439%+5pp
SG&A−0.617%−4pp
Other−0.37%+0pp
Operating profit1.129% margin−1pp
Tax−0.1
Net profit1.438%−3pp
Filing on EDGAR More quarters of REGN

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters